NEW YORK, NY--(Marketwire -02/27/12)- Advances in cancer screening and treatment has caused the death rate from cancer to drop dramatically in recent years. Cancer death rates dropped by 1.8 percent per year in men and 1.6 percent per year in women between 2004 and 2008, according to the American Cancer Society's annual report on cancer statistics. The Paragon Report examines investing opportunities in the Healthcare sector and provides equity research on Geron Corporation (NASDAQ: GERN - News) & Onyx Pharmaceuticals Inc. (NASDAQ: ONXX - News). Access to the full company reports can be found at:
Death rates fell in all four of the most common cancers, lung, colon, breast and prostate, with lung cancer accounting for nearly 40 percent of the total drop in men and breast cancer account for 34 percent of the total decline in women, the American Cancer Society report finds.
The U.S. FDA has been approving cancer drugs at a faster rate than its European counterpart (the EMA), Friends of Cancer Research reports. Between 2003 and 2010, the FDA not only approved more new cancer drugs than did the EMA, it approved these drugs more quickly: of 23 drugs approved by both agencies, the median time from marketing submission to FDA approval was 182 days vs. EMA approval of 350 days according to the report.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Healthcare sector register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. Earlier this month the company completed enrollment in the randomized Phase 2 clinical trial of imetelstat, in combination with paclitaxel, in patients with locally recurrent or metastatic breast cancer (MBC).
Onyx Pharmaceuticals, Inc. discovers and develops novel therapeutics based upon the genetics of human disease, with an emphasis on cancer. The Company focuses on defining the function of certain mutated genes which are known to cause cancer, and on developing therapies to reverse the effects of the mutation or to kill the cancer cell. Onyx reported non-GAAP net income of $42.0 million, or $0.66 per diluted share, for the full year 2011 compared to non-GAAP net income of $39.2 million, or $0.63 per diluted share, for the same period in 2010.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer